Trade Names:Robinul- Tablets 1 mg- Injection 0.2 mg/mL
Trade Names:Robinul Forte- Tablets 2 mg
Exerts anticholinergic effects, resulting in GI smooth muscle relaxation, diminished volume and acidity of GI secretions, and reduced pharyngeal, tracheal, and bronchial secretions.
Absorption is poor and unreliable.
Highly polar ammonium group of glycopyrrolate limits its passage across blood-brain barrier and other lipid membranes.
Within 1 min after IV injection.
30 to 45 min after IM administration.
Vagal blocking effects persist for 2 to 3 h. Antisialagogue effects persist up to 7 hours.
Adjunctive treatment of peptic ulcer.Parenteral
Preoperative administration for reduction of salivary, tracheobronchial and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac vagal inhibitory reflexes before and during induction of anesthesia and intubation; intraoperatively for counteraction of drug-induced or vagal traction reflexes with associated arrhythmias.
Narrow angle glaucoma; adhesions between iris and lens; obstructive uropathy; obstructive disease of GI tract; paralytic ileus; intestinal atony of elderly or debilitated patients; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; hepatic or renal disease; tachycardia; myocardial ischemia; unstable cardiovascular status in acute hemorrhage; myasthenia gravis.
PO 1 to 2 mg 2 or 3 times daily. IM/IV 0.1 to 0.2 mg 3 or 4 times daily.Preanesthetic MedicationAdults
IM 0.004 mg/kg 20 min to 1 h prior to anesthesia.Children younger than 12 yr of age
IM 0.0044 to 0.0088 mg/kg.Children younger than 2 yr of age
IM up to 0.0088 mg/kg.Intraoperative MedicationAdults
IV 0.1 mg. May repeat at 2 to 3 min intervals.Children
IV 0.004 mg/kg (max 0.1 mg in single dose); may repeat at 2 to 3 min intervals.Reversal of Neuromuscular BlockadeAdults and Children
IV 0.2 mg for each 1 mg neostigmine or 5 mg pyridostigmine. Administer simultaneously.
Store parenteral and oral formulations at room temperature.
May cause decreased serum haloperidol levels, worsened schizophrenic symptoms, and tardive dyskinesia.
Because stability of glycopyrrolate is questionable above pH of 6, do not combine in same syringe with methohexital sodium, chloramphenicol sodium succinate, dimenhydrinate, pentobarbital sodium, thiopental sodium, secobarbital sodium, sodium bicarbonate, diazepam, dexamethasone sodium phosphate, or buffered solution of Lactated Ringer's solution.
None well documented.
Palpitations; tachycardia; orthostatic hypotension.
Headache; flushing; nervousness; drowsiness; weakness; dizziness; confusion; insomnia; fever (especially in children); mental confusion or excitement (especially in elderly, even with small doses); CNS stimulation (restlessness, tremor, hallucinations).
Severe allergic reactions including anaphylaxis, urticaria, and dermal manifestations.
Blurred vision; mydriasis; photophobia; cycloplegia; increased IOP; dilated pupils; nasal congestion.
Dry mouth; altered taste perception; nausea; vomiting; dysphagia; heartburn; constipation; bloated feeling; paralytic ileus.
Urinary hesitancy and retention; impotence.
Suppression of lactation; decreased sweating.
Category B .
Not recommended for treatment of peptic ulcer in children younger than 12 yr of age.
May react with excitement, agitation, drowsiness, and other untoward manifestations even with small doses.
Use with caution in patients with autonomic neuropathy, hepatic or renal disease, ulcerative colitis, hyperthyroidism, coronary heart disease, CHF, cardiac tachyarrhythmias, hypertension, prostatic hypertrophy, hiatal hernia associated with reflux esophagitis.
Reported in sensitive individuals; may include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, coma, euphoria, anxiety, fatigue, insomnia, agitation, and inappropriate affect.
May be symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. Treatment of diarrhea with drug is inappropriate and possibly harmful.
May delay gastric emptying rate and complicate therapy.
Can occur in presence of high environmental temperature.
Dry mouth, thirst, vomiting, nausea, abdominal distention, difficulty swallowing, muscular weakness, paralysis, fever, coma, circulatory failure, rapid pulse and respiration, vasodilation, tachycardia with weak pulse, hypertension, hypotension, respiratory depression, palpitations.
Copyright © 2009 Wolters Kluwer Health.